Market Watch: Ginkgo Bioworks Holdings Inc (DNA)’s Noteworthy Gain, Closing at 0.84

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

As of close of business last night, Ginkgo Bioworks Holdings Inc’s stock clocked out at $0.84, up 10.49% from its previous closing price of $0.76. In other words, the price has increased by $10.49 from its previous closing price. On the day, 70.54 million shares were traded. DNA stock price reached its highest trading level at $0.88 during the session, while it also had its lowest trading level at $0.7609.


To gain a deeper understanding of DNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.

On November 14, 2023, Raymond James Downgraded its rating to Mkt Perform which previously was Outperform and also lowered its target price recommendation from $3.50 to $2.50.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Coen Steven P. sold 131,928 shares for $0.84 per share. The transaction valued at 111,479 led to the insider holds 162,527 shares of the business.

Dmytruk Mark E. sold 47,806 shares of DNA for $40,396 on May 02 ’24. The insider now owns 925,400 shares after completing the transaction at $0.84 per share. On Apr 02 ’24, another insider, Dmytruk Mark E., who serves as the insider of the company, sold 51,169 shares for $1.05 each. As a result, the insider received 53,727 and left with 865,079 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 1859022976 and an Enterprise Value of 1253078400. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.39 while its Price-to-Book (P/B) ratio in mrq is 1.63. Its current Enterprise Value per Revenue stands at 6.004 whereas that against EBITDA is -1.987.

Stock Price History:

The Beta on a monthly basis for DNA is 1.38, which has changed by -0.3272 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is -18.56%, while the 200-Day Moving Average is calculated to be -42.75%.

Shares Statistics:

It appears that DNA traded 33.60M shares on average per day over the past three months and 63645420 shares per day over the past ten days. A total of 1.53B shares are outstanding, with a floating share count of 1.39B. Insiders hold about 32.59% of the company’s shares, while institutions hold 56.12% stake in the company. Shares short for DNA as of 1714435200 were 289725988 with a Short Ratio of 8.62, compared to 1711584000 on 270825651. Therefore, it implies a Short% of Shares Outstanding of 289725988 and a Short% of Float of 23.68.

Earnings Estimates

The stock of Ginkgo Bioworks Holdings Inc (DNA) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.1, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.06 and low estimates of -$0.09.

Analysts are recommending an EPS of between -$0.27 and -$0.38 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.25, with 6.0 analysts recommending between -$0.15 and -$0.36.

Revenue Estimates

In the current quarter, 6 analysts expect revenue to total $46.64M. It ranges from a high estimate of $54M to a low estimate of $42.5M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $80.57MFor the next quarter, 6 analysts are estimating revenue of $51.29M. There is a high estimate of $60.1M for the next quarter, whereas the lowest estimate is $45.5M.

A total of 7 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $226M, while the lowest revenue estimate was $173.7M, resulting in an average revenue estimate of $199.27M. In the same quarter a year ago, actual revenue was $251.46MBased on 7 analysts’ estimates, the company’s revenue will be $264.64M in the next fiscal year. The high estimate is $398.3M and the low estimate is $180M.

Most Popular

[the_ad id="945"]